Artiva Biotherapeutics, Inc. Common Stock ARTV
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 2 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $26.33 (+516.7% upside)
Key Stats
- Today's Range
- $4.00 – $4.45
- 50-Day Range
- $4.00 – $12.08
- 52-Week Range
- $2.52 – $14.53
- Volume
- 8.67 million shs
- Average Volume
- 794K shs
- Market Cap
- $301.16 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.06%
- Days to Cover
- 1.00
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Related Stocks
Compare head-to-head: ARTV vs AMGN·ARTV vs MRNA·ARTV vs HALO·ARTV vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.